Last Updated : May 1, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Januvia | Sitagliptin phosphate | Diabetes mellitus (Type 2) | Do not list | Complete | ||
Zeldox | Ziprasidone hydrochloride | Schizophrenia and related psychotic disorders | List with clinical criteria and/or conditions | Complete | ||
Cymbalta | Duloxetine hydrochloride | Pain, Neuropathic, Diabetic | List with clinical criteria and/or conditions | Complete | ||
Cymbalta | Duloxetine hydrochloride | Depressive, Major Disorder (MDD) | Do not list | Complete | ||
Cubicin | Daptomycin | Skin and skin structure infections & bacteremia | Do not list | Complete | ||
Suboxone | Buprenorphine/naloxone | Opioid drug dependence (Substitution treatment) | List with clinical criteria and/or conditions | Complete | ||
Intelence | Etravirine | HIV | List with clinical criteria and/or conditions | Complete | ||
Humira | Adalimumab | Psoriasis | List with clinical criteria and/or conditions | Complete | ||
Stalevo | Carbidopa, levodopa and entacapone | Parkinsons Disease | List in a similar manner | Complete | ||
Thelin | Sitaxsentan sodium | Pulmonary arterial hypertension (WHO class II and III) | Do not list | Complete |